Stock Analysis
BioPorto First Quarter 2024 Earnings: kr.0.04 loss per share (vs kr.0.048 loss in 1Q 2023)
BioPorto (CPH:BIOPOR) First Quarter 2024 Results
Key Financial Results
- Revenue: kr.9.46m (up 18% from 1Q 2023).
- Net loss: kr.13.6m (loss narrowed by 16% from 1Q 2023).
- kr.0.04 loss per share (improved from kr.0.048 loss in 1Q 2023).
All figures shown in the chart above are for the trailing 12 month (TTM) period
BioPorto shares are up 26% from a week ago.
Risk Analysis
Be aware that BioPorto is showing 6 warning signs in our investment analysis and 2 of those are significant...
Valuation is complex, but we're helping make it simple.
Find out whether BioPorto is potentially over or undervalued by checking out our comprehensive analysis, which includes fair value estimates, risks and warnings, dividends, insider transactions and financial health.
View the Free AnalysisHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
About CPSE:BIOPOR
BioPorto
An in-vitro diagnostics company, provides biomarker tools and antibodies for clinical research in Europe, North America, Asia, and internationally.
Adequate balance sheet with weak fundamentals.